The VAD Journal: The journal of mechanical assisted circulation and heart failure

Peer-Reviewed Original Research

Favorable Outcomes of LVAD as
Bridge to Simultaneous Heart-Kidney
Transplantation
Vinay Thohan1*, Ghulam Murtaza2, Carlos O. Encarnacion2, Nasir
Sulemanjee1, Omar Cheema1, Thomas Hastings1, Chi Cho1, Frank Downey1,
and John Crouch1
1
2

Citation: Thohanm V et al.(2016).
" Favorable Outcomes of LVAD
as Bridge to Simultaneous HeartKidney Transplantation”
The VAD Journal, 2. doi:
https://doi.org/10.13023/VAD.201
6.27
Editor-in-Chief: Maya Guglin,
University of Kentucky
Received: September 26, 2016
Accepted: December 4, 2016
Published: December 4, 2016
© 2016 The Author(s). This is an
open access article published
under the terms of the Creative
Commons AttributionNonCommercial 4.0 International
License
(https://creativecommons.org/lice
nses/by-nc/4.0/), which permits
unrestricted non-commercial use,
distribution, and reproduction in
any medium, provided that the
original author(s) and the
publication source are credited.
Funding: Not applicable
Competing interests: Not
applicable

Aurora Cardiovascular Services, Aurora Sinai/Aurora St. Luke's Medical Centers
Medical College of Wisconsin, Milwaukee, WI

* Corresponding author: publishing112@aurora.org

Abstract
Background
Chronic kidney disease (CKD) is an established risk factor for incident
cardiovascular disease and progression of heart failure disease state, and is
associated with decreased survival after left ventricular assist device (LVAD)
therapy or heart transplantation (HT). Combined heart-kidney transplantation
(HKT) compared with isolated HT recently has been shown to have survival
advantage among patients whose estimated glomerular filtration rate is less than
37 ml/min/m2. Data on LVAD to HKT are limited.
Methods
At our center, a total of 803 patients have received HT, 594 patients LVAD
therapy, and 23 patients HKT from single donors; of those 23, 15 were without the
use of LVAD and 8 were after support with LVAD.
Results
Kaplan-Meier survival analysis found LVAD-supported patients with CKD stages 4
or 5 had statistically worse 24-month survival after HT as compared with those
with CKD stage 1, 2, and 3 (58% versus 88%, p=0.01). Patients who received
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combined HKT after LVAD had comparable 24-month survival with those who
received HKT without LVAD (87% and 85%, p=NS); both groups had numerically
better survival compared with those who had CKD (stage 4-5) with isolated HT
(58%).
Conclusions
Patients supported with LVAD who demonstrate advanced CKD (stage 4-5) have
worse 24-month post-HT survival compared with those with less advanced CKD
(stage 1-3). Combined HKT after LVAD support is feasible and confers
comparable 24-month survival compared with HKT without prior LVAD therapy.
Our study supports combined HKT for select LVAD patients with advanced CKD
(stage 4-5).
Keywords: Left ventricular assist device, heart transplant, chronic kidney disease

Introduction
Chronic kidney disease (CKD) as reflected by a lower estimated glomerular
filtration rate (eGFR) is a strong and independent risk factor for both incident
cardiovascular disease and subsequent cardiovascular morbidity and mortality.1-3
Among heart failure patients, lower eGFR is associated with worsening functional
capacity4,5 and nearly double the risk of 12-month hospitalizations or death.6,7
Accordingly, measures of renal function used to develop a variety of acute and
chronic heart failure models confers a proportionally higher risk than many other
common clinical variables.8-10 Patients with heart failure who have deterioration of
renal function exhibit impaired neurohormonal activation, abnormal central
hemodynamics, and reduced cardiac perfusion to the kidneys, commonly
described as cardiorenal syndrome (CRS).11,12 The identification and, especially,
the irreversibility of CRS can signify a clinical spiral characterized by worsening
functional capacity, intolerance to conventional heart failure therapy, and
increased heart failure-related death – a state, often termed advanced heart
failure, in which heart replacement options (left ventricular assist device [LVAD]
therapy or heart transplantation [HT]) are advocated.
LVAD therapy is an excellent treatment option for patients with advanced heart
failure, providing substantive improvements in both quality and quantity of life. 13-17
Clinical trials and INTERMACs data have consistently demonstrated that a high
proportion of patients receiving LVAD therapy have CKD.18,19 Unfortunately,
advanced CKD (stages 3-5) at the time of heart replacement option is a strong
independent predictor of worse 12-month survival with either HT or LVAD.20,21
Most recently, an analysis of the United Network of Organ Sharing (UNOS)
database demonstrated a survival advantage to combined heart-kidney
transplantation (HKT) for heart failure patients with advanced CKD (eGFR<37
ml/min).22 However, limited data exist on the feasibility of LVAD therapy as a
bridge to HKT.23,24 We document safety and favorable outcomes on a small
retrospective cohort of patients who underwent combined HKT after chronic LVAD
therapy.
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Methods
A total of 803 patients underwent HT from 1988-2013; among these, 15 received
combined HKT. A total of 594 patients underwent LVAD therapy, with 256 patients
having had an LVAD prior to HT, including 8 patients who received HKT (19912013). Each HKT was from a single donor with all procedures performed at Aurora
St. Luke’s Medical Center (Milwaukee, WI). This retrospective investigation was
approved by the institutional review board prior to initiation and chart review. All
256 patients had complete clinical data and comprised the final cohort for analysis.
The eGFR was estimated using Modification of Diet in Renal Disease (MDRD)
formulas, and patients were grouped according to established CKD stages.

Statistics
Continuous variables are summarized as mean ± SD and categorical variables are
presented as frequency and percentage, respectively. Differences in continuous
and categorical variables were compared using Wilcoxon Rank-Sum tests and
Pearson chi-square tests, respectively (Table 1). Comparison of survival posttransplant between the LVAD and no LVAD groups were performed using KaplanMeier curves and Log-Rank test (Figures 1 and 2).

Table 1. Baseline characteristics of patient population

LVAD to HT
(n=256)

CKD 1-3
(n=241)

CKD 4-5
(n=15)

p

LVAD to
HKT
(n=8)

HKT
no LVAD
(n=15)

p

Age

54±12

54±12

58±9

0.02

54±9.7

56±8.3

NS

BMI

28±6

28±6

30±7

NS

31±8

27±4.1

NS

Female

48 (19%)

42 (17%)

5 (33%)

0.02

1 (12%)

6 (40%)

0.03

AA race

55 (21%)

7 (47%)

NS

3 (38%)

1 (7%)

NS

CAD

132 (52%)

7 (47%)

0.06

4 (50%)

9 (60%)

NS

eGFR
Support,
days

66±27

48 (20%)
125
(52%)
69±24

21±11

<0.01

19±14

16±12

<0.01

211±214

212±217

190±155

NS

166±100

NS

CKD, chronic kidney disease; LVAD, left ventricular assist device; HKT, heartkidney transplant; BMI, body mass index; AA, African American; CAD, coronary
artery disease; eGFR, estimated glomerular filtration rate.
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Figure 1. Two-year Kaplan-Meier curve showing survival among patients with
chronic kidney disease (CKD) supported with a left ventricular assist device
(LVAD) (1-3) compared with patients with CKD and no LVAD (4-5). HT, heart
transplantation.

Figure 2. Two-year Kaplan-Meier curve showing survival among patients with
combined heart-kidney transplantation (HKT) with and without left ventricular
assist device therapy (LVAD) compared with patients with chronic kidney disease
(CKD) who undergo heart transplantation (HT) alone (4-5).
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Results
Table 1 describes the total cohort of 256 patients; most were young (mean age
54±12) men (n=208, 81%) with coronary artery disease (n=132, 52%), and the
majority (94%) had mild CKD (stage 1-3) at the time of HT, with a mean group
eGFR of 69±24 ml/min. A total of 15 patients had severe CKD (stage 4-5) at the
time of HT, with a mean group eGFR of 21±11; these patients were older (mean
age 58±9) and more often female (n=5, 33%). Comparatively, patients receiving
LVAD to HKT (n=8) vs HKT without LVAD (n=15) were less often female (12% vs
40%, p=0.03) and had slightly higher eGFR (19±14 vs 16±12).
Kaplan-Meier survival analysis (Figure 1) found LVAD-supported patients with
CKD stage 4 or 5 had statistically worse 24-month survival after HT compared with
those with CKD stage 1, 2, or 3 (58% vs 88%, p=0.01). Patients who received
combined HKT after LVAD had comparable 24-month survival with those that
received HKT without LVAD (87% and 85%, p=NS); both groups had numerically
better survival compared with those who had CKD (stages 4 or 5) with isolated HT
(58%).

Discussion
Higher CKD stage, characterized by lower eGFR, is an established risk factor for
incident cardiovascular disease and progression of heart failure disease state, and
impairs survival after advanced heart failure therapies (LVAD or HT).1,4,20,21 Select
studies have demonstrated survival advantages to combined HKT for heart failure
patients with advanced CKD.22,25 Our data demonstrate two important
observations. First, it confirms that patients with advanced CKD (stage 4 and 5)
confer a mortality benefit from combined HKT. Second, patients supported with
LVAD therapy who have advanced CKD (stages 4 or 5) who receive combined
HKT have a 2-year survival rate comparable to those who do not have advanced
CKD who receive isolated HT and patients who receive HKT without prior LVAD
therapy, and numerically higher survival than those patients with advanced CKD
who receive HT alone.
UNOS data reported that between 2008 and 2013, the era encompassing
continuous-flow LVAD therapy and the present research, a total of 370 patients
received HKT, among whom 57 (15.4%) patients where supported with LVAD
therapy; our program has performed combined HKT on 23 patients, among whom
8 (34.8%) were supported with LVAD prior to HKT. Only one prior investigation
has evaluated the feasibility and clinical outcomes of patients supported with
LVAD therapy who received HKT.23 Our cohort is larger, extends follow-up beyond
6 months and demonstrates comparable survival outcomes to a contemporary
cohort of patients who underwent either HKT without LVAD therapy or HT with
advanced CKD. The retrospective and single-center nature of this investigation is
associated with selection bias. However, patients who received HKT irrespective
of LVAD therapy in our program were similar with the exception of female gender;
which was more common among those not receiving LVAD therapy, likely
reflecting the known bias associated with LVAD treatment and body size.
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Conclusions
Patients supported with LVAD therapy who demonstrate advanced CKD (stages 45) have worse 24-month post-HT survival compared with those with less-advanced
CKD (stages 1-3). Combined HKT after LVAD support is feasible and confers
comparable 24-month survival compared with HKT without prior LVAD therapy.
Our study supports combined HKT for select LVAD patients with advanced CKD
(stages 4-5).
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